Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 311 | 47 | 259 |
| Samples | 193 | 36 | 153 |
| Peptides | 143 | 22 | 123 |
Function
FBXO22 · F-box protein 22
This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class and, as a transcriptional target of the tumor protein p53, is thought to be involved in degradation of specific proteins in response to p53 induction. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 139 amino-acid changes on canonical ENST00000308275 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FBXO22 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FBXO22 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 18/612 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Burkitts Lymphoma | 1/32 3% | 2/196 1% |
| Melanoma | 3/210 1% | 20/1899 1% |
| Colorectal Carcinoma | 9/143 6% | 24/3239 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 8/810 1% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| Gastric Carcinoma | 3/74 4% | 8/1809 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 10/2550 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Other Solid Cancers | 0/94 0% | 6/1515 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 6/1390 0% |
| Head and Neck Carcinoma | 1/85 1% | 4/1574 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Ovarian Carcinoma | 1/109 1% | 2/998 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 4/2534 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 2/1592 0% |
| Pancreatic Carcinoma | 3/89 3% | 0/1611 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Other Blood Cancers | 1/61 2% | 2/2725 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
Mutation Distribution
Where FBXO22 is mutated · all tissues, split by cell line vs tissue
How many mutations in FBXO22 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 311 mutations in FBXO22
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|